Exelixis’ (EXEL) partner Ipsen Biopharmaceuticals Canada Inc. received approval of Cabometyx®(cabozantinib) tablets from Health Canada for adults with …

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic …

Today, we see are observing an increased interest in AcelRx Pharmaceuticals (ACRX). The increased investors’ activity …

Playing buy and sell games with the CRISPR gene editing stocks is sometimes based on scientific …

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO  - The aggressive portfolio hosts biotech firms with …

The disease, mucopolysaccharidosis (MPS) type II, also known as the horrible Hunter syndrome is a killer …

We reiterate that undeniably outstanding news about gene therapy is taking time to penetrate investors’ ears. …

Before we sell PTC Therapeutics (PTCT), after the stock had reached and surpassed our latest and …

When the Goal is Reaching into the Future, Pessimists Have No Place on the Ship The …

WE ARE LIVING AN HISTORIC BIOLOGICAL REVOLUTION. Unfortunately, the undeniably outstanding news has not yet penetrated …